Analysis of Antiviral Efficacy and Safety in Patients with Chronic Hepatitis B in Indeterminate Phase

Qian AI; Zhirong ZHAO; Yue WU; Haiwen LI; Shenghao LI; Yongrui YANG

doi:10.12259/j.issn.2095-610X.S20250107

Volume 46 Issue 1

Jan. 2025

Turn off MathJax

Article Contents

Abstract

References

Relative Articles

Article Navigation > Journal of Kunming Medical University > 2025 > 46(1): 51-59

Qian AI, Zhirong ZHAO, Yue WU, Haiwen LI, Shenghao LI, Yongrui YANG. Analysis of Antiviral Efficacy and Safety in Patients with Chronic Hepatitis B in Indeterminate Phase[J]. Journal of Kunming Medical University, 2025, 46(1): 51-59. doi: 10.12259/j.issn.2095-610X.S20250107

Citation:

Qian AI, Zhirong ZHAO, Yue WU, Haiwen LI, Shenghao LI, Yongrui YANG. Analysis of Antiviral Efficacy and Safety in Patients with Chronic Hepatitis B in Indeterminate Phase[J]. Journal of Kunming Medical University, 2025, 46(1): 51-59. doi: 10.12259/j.issn.2095-610X.S20250107

Citation:

PDF( 1046 KB)

Analysis of Antiviral Efficacy and Safety in Patients with Chronic Hepatitis B in Indeterminate Phase

doi: 10.12259/j.issn.2095-610X.S20250107

Qian AI^{1, 2},
Zhirong ZHAO¹,
Yue WU^{1, 2},
Haiwen LI¹,
Shenghao LI^{1
,
,},
Yongrui YANG^{1
,
,}

1.
Center of Liver Disease / Yunnan Clinical Center of Infectious Diseases，The Third People’s Hospital of Kunming，Kunming Yunnan 650041
2.
School of Public Health，Dali University，Dali Yunnan 671003，China

Received Date: 2024-09-05
Available Online: 2024-12-25
Publish Date: 2025-01-17

Abstract

Abstract

Objective To analysis the efficacy and safety of antiviral therapy in patients with chronic hepatitis B virus in indeterminate phase based on the new guidelines （2022 Edition of the Guidelines for the Prevention and Treatment of Chronic Hepatitis B）. Methods A total of 170 patients with newly diagnosed HBV infection who visited the Third People's Hospital of Kunming from August 1, 2020, to July 31, 2024, were selected as study subjects. The clinical indicators of patients with normal ALT in the indeterminate phase were analyzed after 12 weeks, 24 weeks, and 48 weeks of antiviral treatment, as well as those who did not receive antiviral treatment for 48 weeks. Results （1） Among the 170 patients with normal ALT during the indeterminate phase of HBV infection, the treatment group consisted of 125 patients （36 HBeAg positive and 89 HBeAg negative）, while the untreated group had 45 patients. In the treatment group, the HBV-DNA load and HBsAg titer decreased significantly after 48 weeks compared to before treatment, with statistically significant differences （both P < 0.05）. In the untreated group, the HBV-DNA load showed an upward trend, and the HBsAg titer slightly decreased, with statistically significant differences （both P < 0.05）. （2） The CVR rate in the treatment group after 48 weeks was 66.67% （24/36） for HBeAg positive patients and 95.51% （85/89） for HBeAg negative patients, with a statistically significant difference （P < 0.05）. （3） The treatment group showed a significant decrease in GGT and AFP after 48 weeks compared to before treatment, while the untreated group saw an increase in ALT, GGT, and AFP, with statistically significant differences （all P < 0.05）. （4） The fibrosis indicators APRI, FIB-4, and LSM in the treatment group significantly decreased after 48 weeks compared to before treatment, with statistically significant differences （all P < 0.05）. （5） The safety indicators CREA, blood calcium, and blood phosphorus in the treatment group significantly decreased after 48 weeks compared to before treatment, with statistically significant differences （all P < 0.05）. Conclusion Expanding the antiviral treatment indications according to the new guidelines for patients with normal ALT in the indeterminate phase of HBV infection demonstrates good efficacy in controlling HBV-DNA, improving CVR rates, and enhancing fibrosis indicators, while also showing favorable renal safety. However, there may be a risk of osteoporosis due to calcium and phosphorus metabolism disorders, necessitating enhanced monitoring and prevention.
- Chronic hepatitis B virus infection,
- Alanine aminotransferase,
- Indeterminate phase,
- Antiviral treatment

FullText(HTML)

References(20)

References

[1]	尤红,王福生,李太生,等. 慢性乙型肝炎防治指南(2022年版)[J]. 实用肝脏病杂志,2023,26(3):457-478.
[2]	杨雪芳,胥莹,张帮婷. 关注慢性乙型肝炎病毒感染“灰区”患者[J]. 胃肠病学和肝病学杂志,2022,31(8):938-941,946. doi: 10.3969/j.issn.1006-5709.2022.08.019
[3]	Huang D Q,Li X,Le M H,et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase[J]. Clin Gastroenterol Hepatol,2022,20(8):1803-1812. doi: 10.1016/j.cgh.2021.01.019
[4]	Yao K,Liu J,Wang J,et al. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone[J]. J Viral Hepat,2021,28(7):1025-1033. doi: 10.1111/jvh.13511
[5]	庄辉. 不确定期慢性乙型肝炎应否治疗?[J]. 临床肝胆病杂志,2021,37(9):2033-2036. doi: 10.3969/j.issn.1001-5256.2021.09.007
[6]	徐京杭,徐小元,于岩岩. 不确定期慢性HBV感染者可能获益于抗病毒治疗[J]. 临床肝胆病杂志,2021,37(11):2539-2540. doi: 10.3969/j.issn.1001-5256.2021.11.007
[7]	谢艳迪,封波,饶慧瑛. 慢性乙型肝炎防治指南(2022年版)解读[J]. 临床肝胆病杂志,2023,39(7):1553-1559. doi: 10.3969/j.issn.1001-5256.2023.07.007
[8]	庄辉. 不确定期慢性乙型肝炎抗病毒治疗再探讨[J]. 临床肝胆病杂志,2023,39(10):2273-2276. doi: 10.3969/j.issn.1001-5256.2023.10.001
[9]	中联肝健康促进中心. 慢性乙肝“领航项目”启动探索优化1900万患者治疗方案[EB/OL]. (2022-8-16)[2024-11-9]. https://liver.org.cn/portal.php?mod=view&aid=2098.
[10]	万千,陈诹,张鸿,等. 上海浦东新区15~65岁人群乙肝感染状况及危险因素分析[J]. 公共卫生与预防医学,2024,35(5):33-36.
[11]	Liu J,Liang W,Jing W,et al. Countdown to 2030: Eliminating hepatitis B disease,China[J]. Bull World Health Organ,2019,97(3):230-238. doi: 10.2471/BLT.18.219469
[12]	The Lancet. Carving a new path to a hepatitis B cure[J]. Lancet,2019,394(10216):2202.
[13]	Foreman K J,Marquez N,Dolgert A,et al. Forecasting life expectancy ,years of life lost,and all-cause and cause-specific mortality for 250 causes of death : Reference and alternative scenarios for 2016-40 for 195 countries and territories [J]. Lancet,2018,392 (10159): 2052-2090.
[14]	王源. 免疫灰区慢性HBV感染者肝组织学进展人群筛查模型研究[D]. 昆明: 昆明医科大学,2023.
[15]	皇旭,姚磊,邓泽润,等. 481例低病毒载量HBV相关肝硬化患者临床特征分析[J]. 中华肝脏病杂志,2021,29(3):227-233. doi: 10.3760/cma.j.cn501113-20200302-00081
[16]	Wu Z,Ma A L,Xie Q,et al. Significant histological changes and satisfying antiviral efficacy in chronic hepatitis B virus infection patients with normal alanine aminotransferase. Antiviral therapy decision in chronic HBV patients with normal ALT[J]. Clinics and Research in Hepatology and Gastroenterology,2021,45(2):101463. doi: 10.1016/j.clinre.2020.05.011
[17]	余文君,余婷婷,李丽华,等. 血清HBsAg、HBV RNA、GGT及GPR联合检测对慢性HBV感染自然史的诊断价值[J]. 昆明医科大学学报,2024,45(7):99-104. doi: 10.12259/j.issn.2095-610X.S20240715
[18]	杨乐梅,黎荣,刘菲. 血清GP73以及AFP高表达预测慢性乙型肝炎肝纤维化进程的临床研究[J]. 标记免疫分析与临床,2018,25(9):1272-1275.
[19]	陈征,石书梅. 合并肾损伤的乙肝患者的临床及病理分析[J]. 中国中西医结合肾病杂志,2023,24(7):599-600. doi: 10.3969/j.issn.1009-587X.2023.07.016
[20]	宋玉文. TAF治疗中国青岛60岁及以上CHB患者有效性和安全性研究[D]. 青岛: 青岛大学,2023.

Relative Articles(20)

Relative Articles

[1]	Bo TIAN, Yongmei JIN, Haiwen LI, Chongxi LI, Wei ZHANG, Wei GUAN, Haiyun CHEN, Qi XUE, Huirong YANG, Jun LIU. Analysis of the Current Status and Influencing Factors of Metabolic Syndrome in Patients Undergoing Antiretroviral Therapy for AIDS. Journal of Kunming Medical University, 2024, 45(11): 149-154. doi: 10.12259/j.issn.2095-610X.S20241121
[2]	Xuelin XIANG, Hongrui ZHAO, Zhongjie WANG, Yu XIA, Min MA, Huadan WANG, Liping. HE. Social Support Status and Influencing Factors of HIV-infected Patients on Antiviral Therapy. Journal of Kunming Medical University, 2024, 45(9): 156-162. doi: 10.12259/j.issn.2095-610X.S20240924
[3]	Bo TIAN, Jun LIU, Chongxi LI, Wei ZHANG, Meiqin FANG, Haiyun CHEN, Jingping BAI, Xin ZHOU, Lei CHENG, Yongmei JIN. Effect Observation and Influencing Factors Analysis of Rapid Initiation of Antiretroviral Therapy. Journal of Kunming Medical University, 2024, 45(9): 163-167. doi: 10.12259/j.issn.2095-610X.S20240925
[4]	Hongrui ZHAO, Xuelin XIANG, Zhongjie WANG, Yu XIA, Huadan WANG, Min MA, Liping HE. Analysis of Influencing Factors of Perceived Discrimination in HIV-infected Patients Treated with Antiviral Therapy. Journal of Kunming Medical University, 2024, 45(12): 88-93. doi: 10.12259/j.issn.2095-610X.S20241212
[5]	Yanli MA, Cheng FENG, Liqing GUO, Xia GUO, Fengqiong ZHOU, Zhi-hui LIU, Yunhong MA. Application Value of Focused Solution Mode Nursing Intervention in Treatment Compliance and Quality of Life of Patients with Hepatitis C. Journal of Kunming Medical University, 2023, 44(2): 177-180. doi: 10.12259/j.issn.2095-610X.S20230212
[6]	Xiaomei JIN, Jieyan HE, Jichang SHI, Hui XING, Hong WANG, Ju ZHANG, Lijuan DONG, Lihua HUANG, Min CHEN, Zhijuan CHEN, Huichao CHEN. Virus Genotypes and Drug Resistance among HIV/AIDS Patients before Antiretroviral Therapy in Dali Bai Autonomous Prefecture in 2018. Journal of Kunming Medical University, 2023, 44(11): 152-157. doi: 10.12259/j.issn.2095-610X.S20231123
[7]	Bo TIAN, Chongxi LI, Yongmei JIN, Wei GUAN, Haiyun CHEN, Jun LIU. Use and Replacement of Treatment Regimens for AIDS Patients on Antiretroviral Therapy. Journal of Kunming Medical University, 2023, 44(5): 162-167. doi: 10.12259/j.issn.2095-610X.S20230508
[8]	Ti WU, Kang HUANG, Zhirong ZHAO, Haiwen LI, Xiaofei LI, Yongrui YANG. The Efficacy and Safety of Different Antiviral Treatment Regimens in Patients with ALT Elevation and Low Viral Load in the Indeterminate Phase of Chronic Hepatitis B. Journal of Kunming Medical University, 2023, 44(1): 97-103. doi: 10.12259/j.issn.2095-610X.S20230117
[9]	Diandian ZENG, Bo TIAN, Yongmei JIN, Chongxi LI, Fen TENG, Jun LIU. A Cross-sectional Survey on Quality of Life of AIDS Patients with Different Antiretroviral Regimens in Kunming Area. Journal of Kunming Medical University, 2022, 43(12): 147-152. doi: 10.12259/j.issn.2095-610X.S20221227
[10]	Chongxi LI, Guangfeng YIN, Yushu ZHANG, Shanqun GU, Wei ZHANG, Jun LIU, Bo TIAN. Prevalence of Kidney Disease among Pre-ART Patients with HIV Infection in Kunming and The Influencing Factors. Journal of Kunming Medical University, 2022, 43(2): 154-159. doi: 10.12259/j.issn.2095-610X.S20220208
[11]	Li-jia ZHU, Xiao-dan MA, Jiang DUAN, Meng LI, Yong-kun HUANG. Difference Analysis of First Liver Function Indexes of Newborns with Different Gestational Age and Birth Weight. Journal of Kunming Medical University, 2021, 42(3): 121-126. doi: 10.12259/j.issn.2095-610X.S20210330
[12]	Yong-rui YANG, Hai-wen LI, Zhi-rong ZHAO, Lu WANG, Ting JIA, Zhi-jian DONG, Xiao-fei LI, Ni-hong LU. Clinical Efficacy and Safety of Sofosbuvir and Vipatavir in the Treatment of Patients with Chronic Hepatitis C and HCV/HIV co-infection. Journal of Kunming Medical University, 2021, 42(7): 130-136. doi: 10.12259/j.issn.2095-610X.S20210722
[13]	Sheng-hao LI, Jie DING, Qing-qing WANG, Si-qi LIU, Li-juan HUA, Jin-yu DUAN, Bao-li BO, An-rui DU, Guo-ji CHANG, Jun-yi LI. Influencing Factors of Moderate to Severe Liver Injury in Patients with Chronic Hepatitis B and NAFLD. Journal of Kunming Medical University, 2021, 42(7): 77-82. doi: 10.12259/j.issn.2095-610X.S20210712
[14]	Yang Yong Rui , Li Xiao Fei , Liu Jun , Guo Ying Wu , Shen Ling . . Journal of Kunming Medical University, 2018, 39(11): 110-113.
[15]	Lou Jin Cheng , Wu Xin Hua , Chen Xi , Lei Hong Tao , Li Tian Shu , An Liang, Lao Yun Fei . An investigation on the Dropout of Patients with HIV/AIDS Receiving Antiviral Therapy in an Area of Yunnan Province. Journal of Kunming Medical University, 2018, 39(04): 121-124.
[16]	Yang Yong Rui , Li Fei , Yang Yin , Wen Pin Yuan , Feng Yu , Shen Jiu Cheng , Zhang Jian Qing , Shen Ling . . Journal of Kunming Medical University, 2018, 39(10): 126-129.
[17]	Sun Yue , Wei Jia , Lu Yong Ping , Wang Jin , Zou Yu , Wang Yu Xue , Yang Mi . Quantitative Analysis on Staging of Chronic Viral Hepatitis B and Hepatic Fibrosis by Real-time Shear Wave Elastography. Journal of Kunming Medical University, 2016, 37(11): 55-59.
[18]	Yang Yong Rui . . Journal of Kunming Medical University,
[19]	Ma Yan Li . . Journal of Kunming Medical University,
[20]	Zhou Gui . . Journal of Kunming Medical University,